Ibogaine research has advanced meaningfully into Phase 2 clinical trials, with multiple studies currently examining its potential for opioid use disorder, alcohol use disorder, and traumatic brain injury (TBI) with co-occurring PTSD. No Phase 3 trials have been completed, and ibogaine remains Schedule I in the United States, meaning it is not legally available as a medicine domestically outside of approved research settings.

What Is the Current State of Ibogaine Phase 2 Research?

Phase 2 trials are designed to test a treatment's efficacy in a specific patient population while continuing to assess safety, dosing, and tolerability. Currently, several research groups are running or have recently completed Phase 2 studies on ibogaine. The most prominent published result comes from a Stanford University study led by Dr. Nolan Williams, whose findings appeared in Nature Medicine in 2024. That trial treated 30 special operations veterans with ibogaine (combined with magnesium to reduce cardiac risk) at a licensed clinic in Mexico, reporting significant reductions in PTSD symptoms, disability ratings, and depression — with effects persisting at a one-month follow-up.

While that study was observational in design rather than a randomized controlled trial, it generated enough scientific momentum to accelerate formal Phase 2 planning. A subsequent registered trial (ClinicalTrials.gov identifier NCT05765981) is examining similar populations under more controlled conditions, with Stanford and affiliated VA researchers involved in oversight.

Which Organizations Are Sponsoring Active Trials?

Several organizations are driving the current trial landscape:

  • MAPS (Multidisciplinary Association for Psychedelic Studies) has been involved in facilitating research infrastructure, including work on veteran-focused ibogaine protocols in collaboration with Stanford University and Department of Defense-adjacent funders.
  • MindMed has maintained ibogaine (as MM-110, a noribogaine prodrug variant) in its pipeline, with earlier Phase 2 work on opioid use disorder, though timelines have shifted across their public disclosures.
  • DemeRx previously conducted Phase 1b/2a trials on ibogaine hydrochloride for opioid dependence in the UK, producing safety and preliminary efficacy data. Those results have informed current-generation protocol design.
  • Academic medical centers, including institutions in New Zealand and Canada — where ibogaine is not Schedule I — have contributed observational Phase 2 data. Noller et al. (2018) published a 12-month follow-up study from New Zealand showing reduced opioid use in the majority of participants post-treatment.

What Do Phase 2 Results Show So Far?

Across Phase 2 and Phase 2-adjacent studies, several patterns emerge consistently:

  • Opioid use disorder: Multiple studies, including Mash et al. (2018) and Brown & Alper (2018), document that a significant proportion of participants report reduced or eliminated opioid cravings following a single ibogaine session, with effects lasting weeks to months in some individuals.
  • PTSD and TBI: The Cherian et al. (2024) Nature Medicine paper reported a mean 88% reduction in PTSD Checklist for DSM-5 (PCL-5) scores at one month post-treatment in the veteran cohort, a finding that drew wide attention from both the scientific community and Congress.
  • Alcohol use disorder: Earlier-phase data suggest potential, but robust Phase 2 trial results specific to alcohol use disorder remain limited as of 2026.
  • Durability: Davis et al. (2017) found that among individuals who used ibogaine for opioid problems, a meaningful subset reported sustained reductions in use at 12 months, though self-report bias is a recognized limitation in observational designs.
Safety Note: Ibogaine carries a well-documented risk of QT interval prolongation, which can trigger fatal cardiac arrhythmias. All current clinical trials require cardiac screening — including baseline ECG — and medical supervision throughout the acute treatment window. The magnesium co-administration protocol used in some veteran studies is one approach researchers are evaluating to reduce this risk. Individuals should never attempt to extrapolate from trial findings to unsupervised use.

Has Ibogaine Received Any Special FDA Designations?

The FDA has not yet granted ibogaine a Breakthrough Therapy Designation (BTD) as of 2026, though advocates and researchers have discussed pursuing that pathway given the unmet need in opioid use disorder and treatment-resistant PTSD. Breakthrough Therapy Designation would expedite development and review and provide intensive FDA guidance. The absence of a BTD does not preclude ongoing Phase 2 work, but securing one would likely accelerate the timeline toward Phase 3 trials. Researchers and sponsors working in this space have publicly identified BTD as a near-term goal contingent on additional Phase 2 safety and efficacy data.

What Are the Biggest Obstacles Facing Phase 2 and Beyond?

Several challenges complicate the path from Phase 2 to approved medicine:

  • Schedule I status in the US: Ibogaine's classification as a Schedule I controlled substance creates significant regulatory and logistical barriers for domestic trials, including DEA licensing requirements, limited supply chains for research-grade material, and restricted access for researchers.
  • Cardiac safety: The cardiac risk profile requires robust screening protocols and monitoring infrastructure, raising trial costs and complexity. Demonstrating an acceptable safety margin at scale is essential for FDA approval consideration.
  • Trial design: Blinding participants to a substance that produces a dramatic 18–36 hour psychoactive experience is practically difficult, creating challenges for placebo-controlled study designs that regulators typically require.
  • Funding: Most psychedelic research, including ibogaine, depends on a combination of philanthropic funding, smaller biotech investment, and limited federal dollars. The National Institute on Drug Abuse (NIDA) has shown increased interest, but large-scale federal trial funding for ibogaine lags behind other areas.
  • International coordination: Because ibogaine research is more advanced in countries where it is legal — Mexico, Brazil, New Zealand, Portugal — data generated outside the US may not fully satisfy FDA requirements without additional domestically conducted trials.

What Comes Next in the Trial Pipeline?

The most closely watched next step is the formalization of randomized controlled Phase 2 trials building on the Stanford veteran data. Congressional interest has grown — the Veteran Ibogaine and Psychedelic Therapy Act has been discussed in legislative sessions, and the Department of Defense has been identified as a potential funding pathway for TBI and PTSD research specifically. If a well-powered randomized Phase 2 trial produces robust data, a Phase 3 application to the FDA could follow within several years, though no confirmed Phase 3 start dates are publicly registered as of 2026. Internationally, Brazil's ANVISA and other regulatory bodies may move on ibogaine frameworks on independent timelines.

Frequently Asked Questions

Ibogaine remains Schedule I in the US. The only legal pathway to receive it domestically is as a participant in an FDA-approved clinical trial under an active Investigational New Drug (IND) application. Outside of that context, possession and use are federally illegal. Anyone claiming to offer ibogaine treatment legally within the US outside of a registered trial should be approached with serious skepticism.
The best starting point is ClinicalTrials.gov, where you can search for "ibogaine" and filter by status, condition, and location. Each trial listing includes contact information and eligibility criteria. Cardiac history, psychiatric diagnoses, and current medications are common screening factors. Speaking with your physician before applying to any trial is strongly recommended.
Phase 2 trials typically enroll dozens to a few hundred participants and focus on whether the treatment works for the target condition and at what dose, while continuing to monitor safety. Phase 3 trials are larger — often hundreds to thousands of participants — and are designed to confirm efficacy, monitor adverse reactions, and compare the treatment to existing options or placebo. Phase 3 data are what the FDA primarily evaluates in a New Drug Application (NDA).
Published in Nature Medicine in 2024, Cherian et al. treated 30 special operations veterans with ibogaine plus magnesium at a licensed clinic in Mexico. One month after treatment, participants showed a mean 88% reduction in PTSD Checklist scores, significant reductions in depression and anxiety measures, and improved functional disability ratings. The study was observational — not placebo-controlled — which is an important limitation, but the magnitude of the findings prompted substantial scientific and policy interest.
Ibogaine produces a distinctive, intense psychoactive experience lasting 18–36 hours, making it virtually impossible for participants to be unaware of whether they received the active drug or a placebo. This is a shared challenge across psychedelic research. Researchers are exploring active placebos, low-dose comparators, and rater-blinded outcome assessments as partial solutions, but no approach fully replicates the gold-standard double-blind design.
Trial recruitment status changes frequently. As of 2026, ClinicalTrials.gov lists several ibogaine-related studies at various stages, some focused on opioid use disorder and some on TBI or PTSD populations. Checking ClinicalTrials.gov directly and filtering by "recruiting" status is the most reliable way to confirm current availability, as listings are updated by trial sponsors on an ongoing basis.
It is scientifically plausible but not guaranteed. The typical timeline from successful Phase 2 to FDA approval — assuming Phase 3 success — runs five to ten years or more. The cardiac safety profile must be convincingly addressed in large-scale data, and at least one sponsor must commit to the cost of a full Phase 3 program. Regulatory changes, Breakthrough Therapy Designation, or strong legislative support could shorten the timeline. Most researchers characterize approval before 2030 as optimistic but not impossible for a specific indication.

The ibogaine trial landscape is moving faster than at any previous point, driven by the opioid crisis, veteran mental health needs, and a broader shift in regulatory and public attitudes toward psychedelic medicine research. If you are considering participation in a clinical trial, or are a clinician tracking this space, consulting with a physician familiar with psychedelic research and a legal professional aware of your jurisdiction's regulations is the appropriate first step. ClinicalTrials.gov and peer-reviewed databases such as PubMed are the most reliable sources for updated trial information.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.